Due to the COVID-19 pandemic, the ACP office is closed to the public as our staff work remotely. Click here to see how this impacts our programs and operations.

Community pharmacies may see increase in Aromatase Inhibitor prescriptions

September 8, 2009

Funding under the Outpatient Cancer Drug Benefit Program for Aromatase Inhibitors (Anastrozole - Arimidex®, Exemestane - Aromasin®, Letrozole - Femara®), is limited for certain breast cancer indications.

Some patients are now reaching the end of their funded hormone therapy, so if the physician decides to continue the patient’s treatment, the patient will be given a prescription which they will be asked to fill at their community pharmacy.   

If you have questions regarding whether a patient is eligible for coverage under the Outpatient Cancer Drug Benefit Program or whether they will be required to pay for their ongoing treatment, call the appropriate Cancer Care Pharmacy Department for clarification.

  • Cross Cancer Institute Pharmacy Dept.:  (780) 432-8405
  • Tom Baker Cancer Centre Pharmacy Dept.: (403) 521-3344

Originally published in the September 8, 2009, issue of The Link


← Previous ArticleNext Article →